Skip to main content

Table 2 Survival Data

From: A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

 

Cilengitide + Gemcitabine n = 46

Gemcitabine n = 43

Number of deaths

41

37

Median survival (95% CI), days

204 (154–292)

234 (137–290)

1-year survival (95% CI)

0.15 (0.04–0.26)

0.24 (0.11–0.37)

Median PFS (95% CI), days

110 (59–154)

115 (62–178)

  1. Abbreviation: CI, confidence interval.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us